Anthocyanins inhibit trastuzumab-resistant breast cancer in vitro and in vivo

XIN LI¹, JINMEI XU², XI TANG², YILUN LIU², XIAOPING YU³, ZHI WANG² and WEIHUA LIU²

¹Administrative Office, Chengdu Medical College; ²Department of Scientific Research, First Affiliated Hospital of Chengdu Medical College; ³Department of Public Health, Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China

Received February 10, 2015; Accepted November 30, 2015

DOI: 10.3892/mmr.2016.4990

Abstract. Trastuzumab (Herceptin®) is a recombinant humanized monoclonal antibody that is targeted against the human epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor. Trastuzumab has been successfully used to treat patients with HER2-positive breast cancer, which accounts for ~25% of invasive breast cancer. However, the majority of patients who initially respond to trastuzumab demonstrate disease progression within 1 year of treatment. Therefore, identifying alternative drugs that overcome trastuzumab resistance and target HER2 may increase the magnitude and duration of response. Through a high-throughput screening approach, we previously identified numerous anthocyanins that exert activity in HER2-positive human breast cancer cell lines. The present study aimed to evaluate the anti-tumor properties of anthocyanins against parental HER2-positive cells and derivative trastuzumab-resistant cells in vitro and in vivo. Cell proliferation, western blotting, Annexin V staining, migration and invasion assays were used to determine the effects of anthocyanins in vitro. Cyanidin-3-glucoside and peonidin-3-glucoside were able to inhibit phosphorylation of HER2, induce apoptosis, suppress migration and invasion, and inhibit tumor cell growth. Coupled with the fact that anthocyanins have been used for decades as supplements for the treatment of various types of cancer in Asia, the present study may have established a framework for the development and testing of anthocyanins as a novel treatment paradigm used to overcome classical trastuzumab-resistance and to improve the outcome of this disease.

Introduction

In the United States, breast cancer is the second most common cause of cancer-associated mortality in women (1). An estimated 60,290 new cases of breast carcinoma in situ were expected to be diagnosed among women in the US during 2015, according to the American Cancer Society (1). Breast cancer accounts for 7-10% of all malignant tumors, with a 3-4% increase in the number of new cases occurring each year in China (2).

Overexpression of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor gene has been identified as a negative prognostic factor for node-positive early breast cancer; therefore, understanding the biology of HER2 has revolutionized the classification, prognosis, and treatment of breast cancer (3,4). HER2 is known to be overexpressed in 15-20% of breast cancer and has an important role in regulating cell survival, proliferation, angiogenesis, invasion and metastasis (5). At present, targeted anticancer drugs, such as the monoclonal antibody trastuzumab (Herceptin®) have been proven to be effective in clinical settings (6). However, primary resistance to trastuzumab remains a prevalent challenge for the treatment of patients with HER2-positive breast cancer (3). Traditional Chinese herbs and medicines have been reported to be clinically effective in the treatment of cancer; however, the underlying mechanisms of action remain largely unknown. We previously reported a high-throughput in vitro screen of a 10,000 natural product library against six representative breast cancer cell lines, and assessed the cytotoxicity of each drug (7). Out of the eight natural compounds that selectively inhibit the proliferation of HER2-positive cells, two anthocyanins: Peonidin-3-glucoside (P3G) and cyanidin-3-glucoside (C3G) were studied in vitro and in vivo (7). Subsequently, we investigated the combined antitumor effects of P3G or C3G with trastuzumab on representative HER2-positive breast cancer cell lines and on a tumor xenograft model, and demonstrated that the anthocyanins were able to significantly enhance trastuzumab-induced growth inhibition (8).

The present study aimed to characterize the mechanisms underlying the activity of P3G and C3G against HER2-positive trastuzumab-resistant human breast cancer cell lines. Elucidation of the mechanisms of action of P3G and C3G may enhance the understanding of breast cancer and result in identification of novel treatment strategies.
Materials and methods

Reagents. Unless otherwise stated all chemicals and reagents (analytical grade) were purchased from Sigma-Aldrich China, Inc. (Shanghai, China). Trastuzumab was a gift from the Pharmacology Department of Chengdu Medical College (Chengdu, China), and was originally purchased from Roche Diagnostics (Shanghai, China) with >98% purity. P3G and C3G were purchased from Pharmanic (Chengdu, China) with >98% purity.

Cell lines and culture conditions. Parental cells were obtained from the American Type Culture Collection (Manassas, VA, USA). MDA-MB-453 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mmol/l L-glutamine. BT474 cells were maintained in DMEM:Hami’s F12 medium (1:1 mixture) supplemented with 2 mmol/l L-glutamine and 5 µg/ml insulin. Resistant lines (MDA-MB-453R and BT474R) were developed by continuously exposing cells to trastuzumab (8 µg/ml) until the cells regained morphology similar to that of the parental line (~3 months) (9,10). Subsequently, the cells were maintained in 8 µg/ml trastuzumab. All media were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All cells were maintained in an atmosphere containing 5% CO₂ at 37°C. Trastuzumab was removed from the media for subsequent experiments.

Cell proliferation assay. Cell proliferation assays were performed as described previously (7). Briefly, MDA-MB-453, MDA-MB-453R, BT474 and BT474R cells were plated at a density of 1x10⁵ cells/well in a total volume of 90 µl/well (96-well plates). Cells were allowed to attach to the bottom of the plates overnight, and were then treated with or without 10 µl C3G or P3G (concentration range 0.003-50 µM) in a 100 µl total volume, 4-fold dilution for 48 h at 37°C in an atmosphere containing 5% CO₂. Aliquots of Alamar-Blue reagents (20 µl) were added directly to each well, the plates were incubated at 37°C for an additional 3 h, and the fluorescent signal was measured at an excitation wavelength of 530 nm and an emission wavelength of 590 nm using a ZS-2 plate reader (Beijing Hongrunda Technology Development Co., Ltd., Beijing, China). Data were normalized as percentage viability relative to the vehicle control (dimethyl sulfoxide), defined as 100% survival.

Drug treatment for western blotting. MDA-MB-453, MDA-MB-453R, BT474 and BT474R cells were grown to 70-80% confluence, harvested, and aliquoted into 60 mm dishes at a density of 1x10⁶ cells/dish. After an overnight incubation, media were removed and replaced with fresh media supplemented with or without 5 µl/ml C3G or P3G. The dishes were incubated for an additional 24 h prior to harvesting.

Western blot analysis. Western blotting was performed as previously described (7). Briefly, the cells were washed with ice-cold phosphate-buffered saline (PBS) and were scraped into radioimmunoprecipitation assay buffer supplemented with protease inhibitor and phosphatase inhibitor (Roche Diagnostics). The homogenates were centrifuged at the maximum force for 5 min at 4°C. The supernatants were then transferred to fresh tubes, and protein concentrations were determined using the Bio-Rad Protein Assay [Bio-Rad Laboratories (Shanghai) Ltd., Shanghai, China], according to the manufacturer’s protocol. Total protein samples (25 µg) were subjected to electrophoresis [10% Tris-HCL, 1.0 mm gel; Bio-Rad Laboratories (Shanghai) Ltd.] and were transferred to polyvinylidene fluoride membranes (Thermo Fisher Scientific, Shanghai, China). The membranes were then blocked in Tris-buffered saline containing 0.05% Tween 20 (TBST) and 5% nonfat milk or 5% bovine serum albumin (BSA) for 1 h at room temperature. Primary antibodies were diluted to 1:10,000 using SuperBlock (PBS) blocking buffer (Thermo Fisher Scientific), and the membranes were incubated with them for 2 h at room temperature or overnight at 4°C. Following three washes with TBST, the secondary antibodies were diluted to 1:10,000 using Enhanced Chemiluminescence (ECL) Plus Western Blotting Detection system (GE Healthcare, Shanghai, China). Following a 5 min incubation with ECL Plus reagents, the membranes were washed once with TBST, prior to exposure to films. The image was analyzed using ImageJ 1.49 software (National Institutes of Health, Bethesda, MD, USA). The following antibodies purchased from Rui Biological Ltd. (Shanghai, China) were used: Anti-phosphorylated (p)-HER2 (Tyr1248; cat. no. AB-2387), anti-HER2 (cat. no. AB-5569), anti-p-44/42 MAPK (Thr308 or Ser473; cat. no. AB-2864, AB-2865), anti-HER2 (cat. no. AB-2863), anti-p-p42/44 mitogen-activated protein kinase (MAPK) (cat. no. AB-6534), anti-p42/44 MAPK (cat. no. AB-6535), anti-β-actin (cat. no. AB-0230), horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG) (cat. no. AB-0025), and (HRP)-conjugated goat anti-mouse IgG (cat. no. AB-0032).

Annexin V-fluorescein isothiocyanate (FITC) assay. An Annexin V-FITC assay was used to detect early apoptotic effects, as previously described (7). Briefly, the cells were treated with or without reagents for 24 h at 37°C. The cells were then stained with Annexin-V-FITC antibody (cat. no. A13199;Thermo Fisher Scientific, Inc., Waltham, MA, USA; supplied by the Chengdu Medical College Flow-Cytometry Core Facility) for 15 min in the dark on ice. Propidium iodide (PI; 1 g/ml) was added immediately prior to analysis. The cells were analyzed using CyFlow® ML (Sysmex Partec GmbH, Görlitz, Germany). Bivariant analysis was used to define the population of cells, where FITC (-) and PI (-) cells were designated as viable cells, FITC (+) and PI (-) cells were designated as apoptotic cells, and FITC (+) and PI (+) cells were designated as late apoptotic or necrotic cells.

Casparase 3/7 activity assay. The apoptotic effects of drug treatment were assessed using a caspase 3/7 activity assay as described previously (7). Following a 48 h drug treatment, aliquots of Alamar-Blue reagent (20 µl/well) were added directly to each well, the plates were incubated at 37°C for 3 h and the fluorescent signal was recorded at an excitation wavelength of 530 nm, and an emission wavelength of 590 nm, using a ZS-2 plate reader (Beijing Hongrunda Technology Development Co., Ltd.). Subsequently, equal volumes
Migration and invasion assays. Migration and invasion assays were conducted using a Transwell (8 µm; Merck Millipore, Beijing, China) double chamber co-culture system. Briefly, 1x10^4 cells were seeded into the upper chamber of 24-well plates, which were coated with Matrigel (migration assay) or 1 mg/ml type I collagen solution (invasion assay). The lower chamber was filled with media supplemented with 10% FBS. The cells were cultured with medium, or medium supplemented with C3G (1 mg/ml) or P3G (1 mg/ml), for 48 h. The migrated or invaded cells were fixed and stained with crystal violet. Five random fields were selected for each experiment, and were observed under a microscope (SZX16; Olympus Corporation, Tokyo, Japan). Experiments were performed in triplicate.

Mice xenograft model. In vivo experiment protocols were reviewed and approved by the Chengdu Medical College Institutional Animal Care and Use Committee. All in vivo experiments were conducted under pathogen-free conditions at the animal facility. BT474R cells were suspended in PBS (2x10^6 cells/100 µl) and subcutaneously implanted into the flank region of 6-7-week-old female nude mice weighing 18-22 g (Chengdu Medical College Animal Facility, Chengdu, China). The rats had ad libitum access to food and water, and were maintained under controlled lighting (12 h light/dark cycle) and temperature (20-25°C). Once tumors had reached 50-60 mm^3 volume, the mice were randomly assigned to three groups (n=10), receiving either i) intraperitoneal (i.p.) injection of 100 µl PBS (PBS only, twice a week); ii) i.p. injection of C3G (6 mg/kg in 100 µl PBS, twice a week); or iii) i.p. injection of P3G (6 mg/kg in 100 µl PBS, twice a week). Tumors were measured every 5 days. The mice were euthanized once the tumors reached 1,000 mm^3 due to ethical requirements. All animals were euthanized by an overdose of CO2 at the end of the experiment. Tumor tissues were extracted for immunostaining and weighing.

Immunohistochemistry. Spleen, liver and kidney sections from formalin-fixed, paraffin-embedded tumor xenografts (4 µm) were subjected to immunohistochemical staining using anti-HER2 (cat. no. AB-5569), anti-Ki67 (cat. no. AB-2368) and anti-caspase 3 (cat. no. AB-2294) (all Rui Biological Ltd.) antibodies. Briefly, the tissue sections were deparaffinized and rehydrated, followed by treatment with citrate buffer (pH 6.0) and 3% hydrogen peroxide. The sections were then incubated with the primary antibodies for 30-60 min at room temperature, followed by an incubation with HRP-conjugated goat anti-rabbit IgG (cat. no. AB-0025; Rui Biological Ltd.) for 1 h at room temperature. Nuclei were counterstained with hematoxylin. The staining was visualized and recorded using a microscope (SZX16; Olympus Corporation).

Statistical analysis. In vitro data are presented as the mean ± standard deviation (n≥3). In vivo data are presented as the mean ± standard error of the mean (n=10). Data were analyzed by Student's t-test using SigmaPlot version 12.0 (Systat Software, Inc., San Jose, CA, USA). P≤0.05 was considered to indicate a statistically significant difference.

Results

Treatment with C3G or P3G sensitizes trastuzumab-resistant MDA-MB-453R and BT474R cell lines in vitro. To determine the ability of C3G and P3G to overcome trastuzumab resistance, two HER2-positive cell lines (MDA-MB-453 and BT474) and their trastuzumab-resistant cell lines (MDA-MB-453R, BT474R) were treated with 0.003 to 50 µM (4-fold dilution) C3G or P3G for 48 h. The calculated half maximal inhibitory concentration (IC50) value for each cell line was determined (Fig. 1). Treatment with C3G or P3G significantly inhibited cell growth in the parental and trastuzumab-resistant cells, as compared with the control cells (Fig. 1).

Treatment with C3G or P3G inhibits p-HER2, p-AKT and p-MAPK expression levels in vitro. The expression levels of p-HER2, and its downstream mediators AKT and MAPK, were assessed by western blotting. The expression levels of p-HER2, p-AKT (Ser473) and p-p44/42 MAPK were down-regulated in MDA-MB-453, MDA-MB-453R, BT474 and BT474R cells following 24 h treatment with C3G (5 µg/ml) and P3G (5 µg/ml) (Fig. 2).

Treatment with C3G or P3G induces apoptosis in trastuzumab-resistant HER2-positive human breast cancer cells in vitro. The effects of C3G or P3G treatment on apoptosis were assessed by Annexin V and caspase 3/7 activity assays (Fig. 3). Following a 24 h treatment, MDA-MB-453 cells treated with trastuzumab, C3G or P3G exhibited 2.8±0.50, 3.2±0.45 and 4.0±0.34 fold-changes in the number of Annexin V-positive cells, as compared with the control cells, respectively (Fig. 3A). In addition, following a 24 h treatment, MDA-MB-453R cells treated with trastuzumab, C3G or P3G exhibited 1.2±0.45, 3.0±0.38 and 3.5±0.44 fold-changes in the number of Annexin V-positive cells, as compared with the control cells, respectively (Fig. 3A). Following a 24 h treatment, BT474 cells treated with trastuzumab, C3G or P3G exhibited 2.5±0.32, 4.2±0.25 and 5.5±0.40 fold-changes in the number of Annexin V-positive cells, as compared with the control cells, respectively (Fig. 3A). Following a 48 h treatment, BT474R cells treated with trastuzumab, C3G or P3G exhibited 3.1±0.40, 12.0±2.10 and 9.2±1.80 fold-changes in caspase 3/7 activity, as compared with the control cells, respectively (Fig. 3B). Following a 48 h treatment, MDA-MB-453 cells treated with trastuzumab, C3G or P3G exhibited 3.0±0.60, 5.8±2.10 and 9.2±1.80 fold-changes in caspase 3/7 activity, as compared with the control cells, respectively (Fig. 3C).
Furthermore, following a 48 h treatment, BT474R cells treated with trastuzumab, C3G or P3G exhibited 1.1±0.23, 4.4±1.20 and 8.1±1.80 fold-changes in caspase 3/7 activity, as compared with the control cells, respectively (Fig. 3D).
Figure 3. Treatment with cyanidin-3-glucoside (C3G) or peonidin-3-glucoside (P3G) induces cell apoptosis in human epidermal growth factor receptor 2 (HER2)-positive and trastuzumab (Trast)-resistant HER2-positive cell lines. (A and B) MDA-MB-453, MDA-MB-453 resistant (R), BT474 and BT474R cells were treated with dimethyl sulfoxide (DMSO, vehicle), Trast (5 µg/ml), C3G (5 µg/ml) or P3G (5 µg/ml) for 24 h and Annexin V-positive cells were counted using flow cytometry. Graphs exhibit fold-change in Annexin V positive cells. (C and D) MDA-MB-453, MDA-MB-453R, BT474 and BT474R cells were treated with DMSO (vehicle), Trast (5 µg/ml), C3G (5 µg/ml) or P3G (5 µg/ml) for 48 h. Graphs exhibit fold-change in caspase 3/7 activities. Data were normalized as caspase 3/7 activity divided by cell viability. Data are presented as the mean ± standard deviation; *P<0.05; **P>0.05.

Figure 4. Effects of cyanidin-3-glucoside (C3G) and peonidin-3-glucoside (P3G) on the migration and invasion of human epidermal growth factor receptor 2-positive trastuzumab-resistant cells. (A and B) BT474 resistant (R) and (C and D) MDA-MB-435R cells were treated with vehicle, C3G (1 mg/ml) or P3G (1 mg/ml) for 48 h. Representative images of migratory and invasive cells are shown. (B and D) Quantitative analysis of the number of migratory or invasive cells, as determined by counting cells under a microscope. Data are presented as the mean ± standard deviation; *P<0.05.
Treatment with C3G or P3G inhibits invasion and migration of trastuzumab-resistant human breast cancer cells in vitro. As determined by Transwell migration assay, the number of migrated BT474R cells treated with C3G (0.21±0.11) or P3G (0.32±0.15) were significantly lower, as compared with the vehicle-treated control cells (1.0±0.25) (Fig. 4A upper panel and B). In addition, the number of migrated MDA-MB-435R cells treated with C3G (0.32±0.22) or P3G (0.40±0.15) were significantly lower, as compared with the vehicle-treated control cells (1.0±0.12) (Fig. 4C upper panel and D). As determined by Transwell invasion assays, the number of invasive BT474R cells treated with C3G (0.12±0.06) or P3G (0.35±0.12) were significantly lower, as compared with the vehicle-treated control cells (1.0±0.18) (Fig. 4A lower panel and B). Furthermore, the number of invasive MDA-MB-435R cells treated with C3G (0.25±0.22) or P3G (0.42±0.15) were significantly lower, as compared with the vehicle-treated control cells (1.0±0.21) (Fig. 4C lower panel and D).

Treatment with C3G or P3G reduces trastuzumab-resistant cell-mediated tumor growth in vivo. The in vivo anti-trastuzumab-resistant tumor growth activities of C3G or P3G were determined using BT474R cells. A pilot study was conducted to determine drug tolerance at the indicated levels, and no signs of organ damage were observed (8). After the experiment, the harvested kidney, liver and spleen samples from each treatment group were indistinguishable from the control group (Fig. 5A). Histopathological studies demonstrated that tumors treated with C3G or P3G expressed lower levels of HER2, as well as the proliferation marker Ki67, as compared with the control group (Fig. 5B). In addition, tumors treated with C3G or P3G expressed higher levels of caspase 3, as compared with the control group (Fig. 5B). During the experiment, body weight of the mice in the C3G or P3G treatment groups was indistinguishable from those in control groups (Fig. 5C). Mice treated with C3G or P3G exhibited a ~67 or ~88% reduction in tumor volume at day 20, respectively (Fig. 5D), and a ~68 or ~76% reduction in tumor weight at day 20, respectively (Fig. 5E).

Discussion
It has previously been reported that C3G and P3G inhibit G2/M arrest, downregulate cyclin-dependent kinase expression, and induce caspase-3 activation, chromatin condensation and cell death in vitro (11). In addition, mulberry anthocyanins, cyanidin 3-rutinoside and C3G, have been reported to inhibit the migration and invasion of human lung cancer cells (12). Numerous in vivo experiments have also suggested promising anti-tumor activities of anthocyanins. C3G has been shown to inhibit human lung tumor growth in xenograft models, including carcinoma cell A549 and Lewis lung carcinoma cell tumor-bearing models (11,13). In addition, bilberry-derived C3G was able to inhibit intestinal adenoma formation in an
Apc (Min) mouse model (14). Previous preclinical studies have also detected the antitumor efficacy of C3G and P3G (7,11-19).

In our previous study, we confirmed that the pharmacological activity of C3G and P3G alone in HER2-positive cell lines was dependent on the inhibition of HER2 activity (7). In addition, a series of experiments were conducted, which were designed to examine the synergism between C3G and trastuzumab, which demonstrated that anthocyanins were able to significantly enhance trastuzumab-induced growth inhibition in representative HER2-positive cell lines, including MDA-MB-453, BT474 and HCC156 cells in vitro. In addition, treatment with C3G or combination with trastuzumab resulted in a more potent inhibition of tumor growth in a BT474 tumor-bearing mouse model, as compared with the control, C3G or trastuzumab treatment groups. These data supported the need for further studies to explore the therapeutic potential of anthocyanin components in combination with trastuzumab in HER2-positive breast cancer.

The in vitro and in vivo data reported in the present study indicated that C3G or P3G treatment may inhibit the activity of HER2, AKT and MAPK in HER2-positive MDA-MB-453 and BT474 cells, as well as in trastuzumab-resistant MDA-MB-453R and BT474R cells. Treatment with C3G or P3G induced apoptosis in the trastuzumab-resistant cells and suppressed the migration and invasion of these cells. In conclusion, C3G and P3G were able to significantly inhibit the growth of trastuzumab-resistant cells in vitro and in vivo. These results support the requirement for further studies that explore the therapeutic potential of anthocyanins in the treatment of patients with trastuzumab-resistant breast cancer. Further studies with regards to overcoming drug resistance are also essential.

Acknowledgements

The authors of the present study would like to thank the Chengdu Medical College flow-cytometry core facility and the animal core facility for their help conducting in vitro and in vivo studies. The present study was supported by the Sichuan Province Health Bureau (grant no. 110465) and the National Natural Science Foundation of China (grant no. 81273074).

References